These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

526 related articles for article (PubMed ID: 28160567)

  • 41. Pharmaceutical Interference of the EWS-FLI1-driven Transcriptome By Cotargeting H3K27ac and RNA Polymerase Activity in Ewing Sarcoma.
    Heisey DAR; Jacob S; Lochmann TL; Kurupi R; Ghotra MS; Calbert ML; Shende M; Maves YK; Koblinski JE; Dozmorov MG; Boikos SA; Benes CH; Faber AC
    Mol Cancer Ther; 2021 Oct; 20(10):1868-1879. PubMed ID: 34315769
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Inhibition of platelet-derived growth factor-induced cell growth signaling by a short interfering RNA for EWS-Fli1 via down-regulation of phospholipase D2 in Ewing sarcoma cells.
    Nozawa S; Ohno T; Banno Y; Dohjima T; Wakahara K; Fan DG; Shimizu K
    J Biol Chem; 2005 Jul; 280(30):27544-51. PubMed ID: 15919668
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Synthesis and structure-activity relationship studies of small molecule disruptors of EWS-FLI1 interactions in Ewing's sarcoma.
    Tosso PN; Kong Y; Scher L; Cummins R; Schneider J; Rahim S; Holman KT; Toretsky J; Wang K; Üren A; Brown ML
    J Med Chem; 2014 Dec; 57(24):10290-303. PubMed ID: 25432018
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Englerin A Inhibits EWS-FLI1 DNA Binding in Ewing Sarcoma Cells.
    Caropreso V; Darvishi E; Turbyville TJ; Ratnayake R; Grohar PJ; McMahon JB; Woldemichael GM
    J Biol Chem; 2016 May; 291(19):10058-66. PubMed ID: 26961871
    [TBL] [Abstract][Full Text] [Related]  

  • 45. EWS-FLI1 positively regulates autophagy by increasing ATG4B expression in Ewing sarcoma cells.
    Lu Q; Zhang Y; Ma L; Li D; Li M; Li J; Liu P
    Int J Mol Med; 2017 Oct; 40(4):1217-1225. PubMed ID: 28902354
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Selective inhibition of HDAC6 regulates expression of the oncogenic driver EWSR1-FLI1 through the EWSR1 promoter in Ewing sarcoma.
    García-Domínguez DJ; Hajji N; Sánchez-Molina S; Figuerola-Bou E; de Pablos RM; Espinosa-Oliva AM; Andrés-León E; Terrón-Camero LC; Flores-Campos R; Pascual-Pasto G; Robles MJ; Machado I; Llombart-Bosch A; Magagnoli G; Scotlandi K; Carcaboso ÁM; Mora J; de Álava E; Hontecillas-Prieto L
    Oncogene; 2021 Sep; 40(39):5843-5853. PubMed ID: 34345016
    [TBL] [Abstract][Full Text] [Related]  

  • 47. ETV6 dependency in Ewing sarcoma by antagonism of EWS-FLI1-mediated enhancer activation.
    Gao Y; He XY; Wu XS; Huang YH; Toneyan S; Ha T; Ipsaro JJ; Koo PK; Joshua-Tor L; Bailey KM; Egeblad M; Vakoc CR
    Nat Cell Biol; 2023 Feb; 25(2):298-308. PubMed ID: 36658219
    [TBL] [Abstract][Full Text] [Related]  

  • 48. NAMPT inhibitor and metabolite protect mouse brain from cryoinjury through distinct mechanisms.
    Zhang XQ; Lu JT; Jiang WX; Lu YB; Wu M; Wei EQ; Zhang WP; Tang C
    Neuroscience; 2015 Apr; 291():230-40. PubMed ID: 25684751
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Lysyl oxidase is downregulated by the EWS/FLI1 oncoprotein and its propeptide domain displays tumor supressor activities in Ewing sarcoma cells.
    Agra N; Cidre F; García-García L; de la Parra J; Alonso J
    PLoS One; 2013; 8(6):e66281. PubMed ID: 23750284
    [TBL] [Abstract][Full Text] [Related]  

  • 50. EWS::FLI1 and HOXD13 Control Tumor Cell Plasticity in Ewing Sarcoma.
    Apfelbaum AA; Wu F; Hawkins AG; Magnuson B; Jiménez JA; Taylor SD; Wrenn ED; Waltner O; Pfaltzgraff ER; Song JY; Hall C; Wellik DM; Ljungman M; Furlan SN; Ryan RJH; Sarthy JF; Lawlor ER
    Clin Cancer Res; 2022 Oct; 28(20):4466-4478. PubMed ID: 35653119
    [TBL] [Abstract][Full Text] [Related]  

  • 51. LIN28B Underlies the Pathogenesis of a Subclass of Ewing Sarcoma LIN28B Control of EWS-FLI1 Stability.
    Keskin T; Bakaric A; Waszyk P; Boulay G; Torsello M; Cornaz-Buros S; Chevalier N; Geiser T; Martin P; Volorio A; Iyer S; Kulkarni A; Letovanec I; Cherix S; Cote GM; Choy E; Digklia A; Montemurro M; Chebib I; Nielsen PG; Carcaboso AM; Mora J; Renella R; Suvà ML; Fusco C; Provero P; Rivera MN; Riggi N; Stamenkovic I
    Cell Rep; 2020 Mar; 30(13):4567-4583.e5. PubMed ID: 32234488
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A novel oncogenic mechanism in Ewing sarcoma involving IGF pathway targeting by EWS/Fli1-regulated microRNAs.
    McKinsey EL; Parrish JK; Irwin AE; Niemeyer BF; Kern HB; Birks DK; Jedlicka P
    Oncogene; 2011 Dec; 30(49):4910-20. PubMed ID: 21643012
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The orphan nuclear receptor DAX1 is up-regulated by the EWS/FLI1 oncoprotein and is highly expressed in Ewing tumors.
    Mendiola M; Carrillo J; García E; Lalli E; Hernández T; de Alava E; Tirode F; Delattre O; García-Miguel P; López-Barea F; Pestaña A; Alonso J
    Int J Cancer; 2006 Mar; 118(6):1381-9. PubMed ID: 16206264
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Long noncoding RNA EWSAT1-mediated gene repression facilitates Ewing sarcoma oncogenesis.
    Marques Howarth M; Simpson D; Ngok SP; Nieves B; Chen R; Siprashvili Z; Vaka D; Breese MR; Crompton BD; Alexe G; Hawkins DS; Jacobson D; Brunner AL; West R; Mora J; Stegmaier K; Khavari P; Sweet-Cordero EA
    J Clin Invest; 2014 Dec; 124(12):5275-90. PubMed ID: 25401475
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Novel peptide binds EWS-FLI1 and reduces the oncogenic potential in Ewing tumors.
    Erkizan HV; Scher LJ; Gamble SE; Barber-Rotenberg JS; Sajwan KP; Üren A; Toretsky JA
    Cell Cycle; 2011 Oct; 10(19):3397-408. PubMed ID: 21926473
    [TBL] [Abstract][Full Text] [Related]  

  • 56. MiR-193b, downregulated in Ewing Sarcoma, targets the ErbB4 oncogene to inhibit anchorage-independent growth.
    Moore C; Parrish JK; Jedlicka P
    PLoS One; 2017; 12(5):e0178028. PubMed ID: 28542597
    [TBL] [Abstract][Full Text] [Related]  

  • 57. High ALDH activity identifies chemotherapy-resistant Ewing's sarcoma stem cells that retain sensitivity to EWS-FLI1 inhibition.
    Awad O; Yustein JT; Shah P; Gul N; Katuri V; O'Neill A; Kong Y; Brown ML; Toretsky JA; Loeb DM
    PLoS One; 2010 Nov; 5(11):e13943. PubMed ID: 21085683
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Catalytic inhibition of KDM1A in Ewing sarcoma is insufficient as a therapeutic strategy.
    Romo-Morales A; Aladowicz E; Blagg J; Gatz SA; Shipley JM
    Pediatr Blood Cancer; 2019 Sep; 66(9):e27888. PubMed ID: 31207107
    [TBL] [Abstract][Full Text] [Related]  

  • 59. GLI1 is a central mediator of EWS/FLI1 signaling in Ewing tumors.
    Joo J; Christensen L; Warner K; States L; Kang HG; Vo K; Lawlor ER; May WA
    PLoS One; 2009 Oct; 4(10):e7608. PubMed ID: 19859563
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Targeting the NAD
    Ye C; Qi L; Li X; Wang J; Yu J; Zhou B; Guo C; Chen J; Zheng S
    Cell Commun Signal; 2020 Jan; 18(1):16. PubMed ID: 32005247
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.